Veradigm Earnings Call Transcripts
Fiscal Year 2026
-
Reset, Recover, Reignite plan is underway, with discontinued low-revenue products and capital reallocated to growth bets. 2025 revenue was flat, but operational and AI-driven initiatives are expected to drive growth and profitability in 2026. SEC filing progress continues, with the Super K as the next milestone.
Fiscal Year 2025
-
Revenue and cash positions remain stable, with 2025 revenue expected flat versus 2024 and a net cash positive outlook. Progress continues on SEC filings and relisting, targeted for 2026, while operational focus is on profitability, growth, and leveraging data assets.
-
Q1 2025 saw over $30 million in new contract value, flat overall revenue, and strong recurring revenue. Operational improvements, audit remediation, and a new credit facility support stability, while growth continues in payer, provider, and life sciences segments.
Fiscal Year 2024
-
Audited 2022 and unaudited 2023–2024 results show 2024 revenue and EBITDA below guidance due to attrition, implementation delays, and sector softness. Remediation of internal controls and audit completion expected by 2026, with 2025 revenue flat and net cash positive.